Goal to improve the treatment environment for cancer patients andreduce the burden on medical staff
Development of ‘OncoStudio,’ anautomated contouring software using AI
Operation of customized technicalsupport for hospitals and a rapid feedback system
Conducting R&D for innovation in thefield of radioligand therapy
[BioTimes] The primary goal of radiation therapy is to minimize the radiation dose to normal organs while delivering a concentrated high dose to the tumor. This requires a precise contouring process to define the boundaries between normal organs and the tumor. Previously, medical staff spent over 3-4 hours per patient performing this contouring work manually.
To improve this essential yet cumbersome and time-consuming process, Oncosoft is developing software solutions that enhance the accuracy and efficiency of radiation therapy using AI-based medical image analysis technology. The company is also developing various other solutions to support the entire radiation therapy process. With its innovative AI-based radiation therapy solutions, Oncosoft aims to improve the treatment environment for cancer patients, reduce the burden on medical staff, and ultimately provide better treatment outcomes.
We spoke with CEO Kim Jinsung to learn more.
Developing AI Medical Solutions That Are Genuinely Helpful
Oncosoft was founded in 2019 to enhance the precision of radiation therapy. CEO Kim Jinsung is a professor at Yonsei University College of Medicine and researches medical physics at Yonsei Cancer Center. He has been a pioneer in introducing heavy ion therapy in Korea and has researched AI technology to improve the precision of radiation therapy. He has also gained extensive experience by applying cutting-edge radiation therapy technologies in clinical settings, operating proton therapy machines at the National Cancer Center and Samsung Medical Center.
CEO Kim stated, "As a medical physicist introducing cutting-edge treatment technologies like proton and heavy ion therapy to clinical practice, I realized that AI-based auto-contouring technology could dramatically improve the efficiency and accuracy of radiation therapy." He added, "However, existing medical AI solutions had several limitations for practical clinical application, which motivated me to develop a reliable AI solution myself."
Oncosoft's flagship product, 'OncoStudio,' is an AI-powered auto-contouring software that improves the precision of radiation therapy and reduces the workload of medical staff. The software analyzes medical images such as CT and MRI scans to automatically segment areas necessary for treatment, including targets and organs at risk.
Using OncoStudio, normal organs can be analyzed in under a minute, a stark contrast to traditional contouring methods. Tumor tissues are also analyzed more quickly and precisely using auto-segmentation technology powered by the latest large language models (LLM). Currently, the normal organ auto-segmentation feature of OncoStudio is approved by the Ministry of Food and Drug Safety and is available on the market, while the advanced LLM-based model is undergoing the regulatory approval process.
CEO Kim explained, "Medical staff can dramatically reduce their working hours and achieve high-quality, highly consistent segmentation." He added, "It also enables the analysis of radiation dosage to detailed structures of the heart, which were previously unanalyzed, contributing to the prediction and prevention of potential side effects from radiation therapy."
Oncosoft's other product, ‘OncoFlow,’ is an integrated workflow management software for radiation therapy. Radiation therapy is a complex process that requires the use of various treatment devices and software. OncoFlow helps reduce the inefficiencies that arise from this process and optimizes the workflow. It is an expanded version of the patient management systems currently used in some large hospitals, serving as an integrated platform that supports the systematic management of the entire radiation therapy process, including cancer patients' treatment details and schedules.
In addition, the company is developing 'OncoRLT,' a web-based platform for radioligand therapy (RLT) planning and workflow management. In conventional RLT, precise dosimetry calculations were cumbersome. OncoRLT provides an easy overview of the entire treatment process and supports precise dose calculation and treatment monitoring.
"As a data-driven approach to treatment becomes essential in the modern medical environment, OncoFlow will increasingly become an indispensable software," said CEO Kim. "OncoRLT enables the development of new radioligand therapies, patient information management, and tumor treatment tracking, facilitating more efficient and precise treatment."
Providingan Integrated Solution to Support the Entire Radiation Therapy Cycle
After obtaining domestic regulatory approval in 2022, Oncosoft made its market entry. Currently, major university hospitals, including Samsung Medical Center and Severance Hospital, and over 20 other advanced general hospitals are using Oncosoft's AI solutions.
The company has also gained recognition for its competitiveness in the global market. In 2024, it won second place at the AI Contouring Competition hosted by the Japanese Society for Radiation Oncology (JASTRO), drawing attention from radiation oncology departments in Japan. Recently, OncoStudio, which received U.S. FDA 510(k) clearance, and the in-development OncoFlow have entered into a joint research agreement with the Mayo Clinic, one of the top cancer hospitals in the United States.
CEO Kim emphasized, "Oncosoft goes beyond simply providing AI solutions; we operate a hospital-customized technical support and rapid feedback system." He added, "While foreign products are often slow with technical support and updates, Oncosoft quickly reflects the hospital's needs and maximizes collaboration with medical staff through continuous upgrades and technical support."
"Oncosoft is leading innovation not only in conventional radiation therapy but also in the growing field of RLT, which is opening up a new paradigm," he continued. "With the success of next-generation radiopharmaceuticals like Pluvicto gaining attention, Oncosoft is developing a comprehensive treatment platform and precise dosimetry software. We plan to provide an integrated solution that supports the entire cycle of radiation therapy."
Oncosoft aims to generate meaningful revenue this year. With the investment secured from a Series B funding round last year, the company is actively pursuing overseas regulatory approvals and global business expansion, while also focusing on the development of new solutions, ‘OncoPlan’ and ‘OncoRLT’. Through these efforts, the company plans to advance the paradigm of radiation therapy. Furthermore, it seeks to open new possibilities for AI-based precision medicine through various partnerships. Based on this growth, Oncosoft aims to begin the process of going public starting in 2026.
CEO Kim shared his vision, "We aim to develop software that innovates the complex and difficult process of cancer treatment, assisting medical professionals in their decision-making and providing better treatment to patients." He concluded, "We will develop solutions based on the accuracy and safety of our technology so that AI can be trusted in the clinical field, and we will work closely with medical staff to create a warmer medical experience for patients."
